Drugs in Dev. Cardiology/Vascular Diseases
Phase II
Canada 
Lead Product(s) : ACP-01
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Mcgill University Health Centre
Deal Size : $0.2 million
Deal Type : Funding
Details : The funding will be used to complete a phase II double blind randomized clinical trial of ACP-01, an autologous angiogenic cell precursor, as a treatment of ischemic cardiomyopathy at the McGill University Health Centre.
Product Name : ACP-01
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 23, 2023
Lead Product(s) : ACP-01
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Mcgill University Health Centre
Deal Size : $0.2 million
Deal Type : Funding
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew
Details : The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy.
Product Name : Epidex
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 06, 2022
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocyte
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
